Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

Episode 10: ASCO Annual Meeting 2024 Commentary: Bladder Cancer

Episode 10: ASCO Annual Meeting 2024 Commentary: Bladder Cancer

FromThe View on GU | with Lalani and Wallis


Episode 10: ASCO Annual Meeting 2024 Commentary: Bladder Cancer

FromThe View on GU | with Lalani and Wallis

ratings:
Length:
23 minutes
Released:
Jun 5, 2024
Format:
Podcast episode

Description

Continuing their conversation from Episode 9, our hosts discuss new findings from the bladder cancer trials and research shared in the #ASCO24 Chicago sessions.Continuing their conversation from Episode 9, Dr. Aly-Khan Lalani and Dr. Christopher Wallis discuss new findings from the bladder cancer trials and research shared in the 2024 ASCO Annual Meeting in Chicago, Illinois. Our hosts start in the metastatic space looking at the 901 trial and move into a perioperative discussion about bladder preservation and the importance of being multi-disciplinary. The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practicing clinicians in the field of genitourinary (GU) cancers.
Learn more about The View on GU: https://theviewongu.com
This podcast has been made possible through financial support by AstraZeneca, Bristol Myers Squibb, Merck, and TerSera.
Released:
Jun 5, 2024
Format:
Podcast episode

Titles in the series (11)

There is currently a lack of organic multi-disciplinary discussion on what is truly impactful to the field of genitourinary (GU) cancers. The View on GU with Lalani and Wallis is a podcast that will integrate key clinical data from major conferences and high impact publications into meaningful take home messages for practicing clinicians. Importantly, Lalani and Wallis will also discuss the impact of governmental approvals and funding considerations on the GU oncology treatment landscape and provide practical considerations on the management of patients on new-to-market therapies.